Ginsenoside panaxatriol [49] induces the transition of breast cancer stem cells into normal breast cancer cells by repressing paclitaxel-resistant breast cancer stem cell-associated genes (OCT4, SOX2, NANOG, CD44, ALDH1) and by inhibiting IRAK1/NF-κB and ERK pathway reduced inflammatory cytokines (IL-6, IL-8, CXCL1, CCL2) expression, which contributed to resensitization of paclitaxel-resistant cells to paclitaxel. The gene discussed is IL6; the disease is breast carcinoma.